Browse by Journal Title

2022

Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas.
Staudacher, J.J., Arnold, A., Kühl, A.A., Pötzsch, M., Daum, S., Winterfeld, M., Berg, E., Hummel, M., Rau, B., Stein, U. and Treese, C.
BMC Cancer 22 (1): 953. 5 September 2022

Pre-diagnostic C-reactive protein concentrations, CRP genetic variation and mortality among individuals with colorectal cancer in Western European populations.
Nimptsch, K., Aleksandrova, K., Fedirko, V., Jenab, M., Gunter, M.J., Siersema, P.D., Wu, K., Katzke, V., Kaaks, R., Panico, S., Palli, D., May, A.M., Sieri, S., Bueno-de-Mesquita, B., Standahl, K., Sánchez, M.J., Perez-Cornago, A., Olsen, A., Tjønneland, A., Bonet, C.B., Dahm, C.C., Chirlaque, M.D., Fiano, V., Tumino, R., Barricarte Gurrea, A., Boutron-Ruault, M.C., Menegaux, F., Severi, G., van Guelpen, B., Lee, Y.A. and Pischon, T.
BMC Cancer 22 (1): 695. 24 June 2022

FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
Raschzok, N., Stintzing, S., Heinemann, V., Rauch, G., Ricke, J., Guckenberger, M., Kurreck, A., Alig, A.H.S., Stahler, A., Bullinger, L., Schmelzle, M., Schöning, W., Lurje, G., Krenzien, F., Haase, O., Rau, B., Gebauer, B., Sauer, I.M., Pratschke, J. and Modest, D.P.
BMC Cancer 22 (1): 359. 2 April 2022

2021

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin.
Gillissen, B., Richter, A., Essmann, F. and Kemmner, W.
BMC Cancer 21 (1): 971. 30 August 2021

2020

Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
Akpa, C.A., Kleo, K., Oker, E., Tomaszewski, N., Messerschmidt, C., López, C., Wagener, R., Oehl-Huber, K., Dettmer, K., Schoeler, A., Lenze, D., Oefner, P.J., Beule, D., Siebert, R., Capper, D., Dimitrova, L. and Hummel, M.
BMC Cancer 20 (1): 427. 14 May 2020

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler, J.K., Brandes, F., Baur, A., Pfitzner, B.M., Kaul, D., Rau, D., Dörr, A., Schmiester, M., Koulaxouzidis, G., Bullinger, L., Märdian, S. and Flörcken, A.
BMC Cancer 20 (1): 68. 29 January 2020

2019

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch, L., Radke, J., Klaus, A., Schwiebert, S., Winkler, A., Schumann, E., Grunewald, L., Zirngibl, F., Flemmig, C., Jensen, M.C., Rossig, C., Joussen, A., Henssen, A., Eggert, A., Schulte, J.H. and Künkele, A.
BMC Cancer 19 (1): 895. 9 September 2019

2018

Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
Burock, S., Daum, S., Keilholz, U., Neumann, K., Walther, W. and Stein, U.
BMC Cancer 18 (1): 297. 15 March 2018

2017

Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
Pahle, J., Menzel, L., Niesler, N., Kobelt, D., Aumann, J., Rivera, M. and Walther, W.
BMC Cancer 17 (1): 129. 13 February 2017

2015

Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study.
Koelzer, V.H., Herrmann, P., Zlobec, I., Karamitopoulou, E., Lugli, A. and Stein, U.
BMC Cancer 15 (1): 160. 21 March 2015

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.
Berenstein, R., Blau, O., Nogai, A., Waechter, M., Slonova, E., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Doerken, B. and Blau, I.W.
BMC Cancer 15 (1): 68. 18 February 2015

2014

Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
Pelzer, U., Hilbig, A., Stieler, J.M., Bahra, M., Sinn, M., Gebauer, B., Doerken, B. and Riess, H.
BMC Cancer 14 (1): 204. 19 March 2014

Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma.
Fehlker, M., Huska, M.R., Joens, T., Andrade-Navarro, M.A. and Kemmner, W.
BMC Cancer 14 (1): 64. 5 February 2014

2013

Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.
Vlaicu, P., Mertins, P., Mayr, T., Widschwendter, P., Ataseven, B., Högel, B., Eiermann, W., Knyazev, P. and Ullrich, A.
BMC Cancer 13 : 197. 18 April 2013

Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma.
Wang, Q., Ma, C. and Kemmner, W.
BMC Cancer 13 (1): 137. 21 March 2013

2012

MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells.
Gregersen, L.H., Jacobsen, A., Frankel, L.B., Wen, J., Krogh, A. and Lund, A.H.
BMC Cancer 12 : 232. 12 June 2012

2010

SERPINB5 and AKAP12 - expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma.
Mardin, W.A., Petrov, K.O., Enns, A., Senninger, N., Haier, J. and Mees, S.T.
BMC Cancer 10 : 549. 12 October 2010

Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study.
Pelzer, U., Arnold, D., Govercin, M., Stieler, J., Doerken, B., Riess, H. and Oettle, H.
BMC Cancer 10 (1): 86. 9 March 2010

2009

Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society.
Siegel, R., Burock, S., Wernecke, K.D., Kretzschmar, A., Dietel, M., Loy, V., Koswig, S., Budach, V. and Schlag, P.M.
BMC Cancer 9 (1): 50. 6 February 2009

2008

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy.
Riess, H., Pelzer, U., Hilbig, A., Stieler, J., Opitz, B., Scholten, T., Kauschat-Bruning, D., Bramlage, P., Doerken, B. and Oettle, H.
BMC Cancer 8 (1): 361. 5 December 2008

Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Korff, S., Woerner, S.M., Yuan, Y.P., Bork, P., von Knebel Doeberitz, M. and Gebert, J.
BMC Cancer 8 (1): 329. 10 November 2008

2007

Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study.
Hildebrandt, B., Mueller, C., Pezzutto, A., Daniel, P.T., Doerken, B. and Scholz, C.
BMC Cancer 7 : 185. 3 October 2007

Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: A phase II-study and historical comparison with the surgical approach.
Hildebrandt, B., Pech, M., Nicolaou, A., Langrehr, J.M., Kurcz, J., Bartels, B., Miersch, A., Felix, R., Neuhaus, P., Riess, H., Doerken, B. and Ricke, J.
BMC Cancer 7 : 69. 24 April 2007

2006

Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
Sturm, I., Rau, B., Schlag, P.M., Wust, P., Hildebrandt, B., Riess, H., Hauptmann, S., Doerken, B. and Daniel, P.T.
BMC Cancer 6 : 124. 10 May 2006

Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway.
Habermehl, D., Kammerer, B., Handrick, R., Eldh, T., Gruber, C., Cordes, N., Daniel, P.T., Plasswilm, L., Bamberg, M., Belka, C. and Jendrossek, V.
BMC Cancer 6 : 14. 17 January 2006

2005

In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.
Sturm, I., Bosanquet, A.G., Hummel, M., Doerken, B. and Daniel, P.T.
BMC Cancer 5 : 105. 18 August 2005

Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis.
Marini, P., Schmid, A., Jendrossek, V., Faltin, H., Daniel, P.T., Budach, W. and Belka, C.
BMC Cancer 5 : 5. 14 January 2005

Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.
Reimer, T.A., Anagnostopoulos, I., Erdmann, B., Lehmann, I., Stein, H., Daniel, P., Doerken, B. and Rehm, A.
BMC Cancer 5 (1): 47. 1 January 2005